Literature DB >> 18374550

On the mechanism of drug release from oil suspensions in vitro using local anesthetics as model drug compounds.

Susan Weng Larsen1, Anna Buus Frost, Jesper Østergaard, Hermann Marcher, Claus Larsen.   

Abstract

The objective of this study was to gain insight into factors influencing the drug release kinetics from oil suspensions. The in vitro drug release from suspensions was investigated at pH 7.4 using the local anesthetics, bupivacaine and ropivacaine, as model drug compounds. Two dialysis membrane-based in vitro release models differing with respect to stirring of the donor compartment were employed to study the release characteristics of oil suspensions comprising the free base or the corresponding drug hydrochloride salt. In the rotating dialysis cell model identical release profiles from aqueous and oil suspensions of the base form were obtained for both ropivacaine and bupivacaine. From the steady state fluxes, drug concentrations in the aqueous donor compartment were found to be in agreement with drug solubilities at pH 7.4. Also relatively fast transformation of a sesame oil suspension of the oil insoluble ropivacaine hydrochloride salt into an aqueous suspension of ropivacaine base was observed. Collectively, these observations indicate a lability of the oil film surrounding the solid particles eventually caused by rotation of the donor cell. In the Float A Lyzer model, which operates at much less intensive stirring, significantly slower release rates from aqueous and oil suspensions of ropivacaine base were obtained. In the latter model, ropivacaine was released faster from oil suspensions containing the hydrochloride salt than from the corresponding oil suspensions of the free base form. These findings suggest that the oil film surrounding the particles also is instable in the absence of significant shear forces.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18374550     DOI: 10.1016/j.ejps.2008.02.005

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  7 in total

Review 1.  Critical factors influencing the in vivo performance of long-acting lipophilic solutions--impact on in vitro release method design.

Authors:  Susan Weng Larsen; Claus Larsen
Journal:  AAPS J       Date:  2009-11-06       Impact factor: 4.009

2.  FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage forms.

Authors:  Cynthia K Brown; Horst Dieter Friedel; Amy R Barker; Lucinda F Buhse; Susanne Keitel; Todd L Cecil; Johannes Kraemer; J Michael Morris; Christos Reppas; Mary P Stickelmeyer; Chikako Yomota; Vinod P Shah
Journal:  AAPS PharmSciTech       Date:  2011-06-18       Impact factor: 3.246

3.  Design and in vitro haemolytic evaluation of cryptolepine hydrochloride-loaded gelatine nanoparticles as a novel approach for the treatment of malaria.

Authors:  Noble Kuntworbe; Raida Al-Kassas
Journal:  AAPS PharmSciTech       Date:  2012-04-05       Impact factor: 3.246

Review 4.  Accelerated in-vitro release testing methods for extended-release parenteral dosage forms.

Authors:  Jie Shen; Diane J Burgess
Journal:  J Pharm Pharmacol       Date:  2012-03-08       Impact factor: 3.765

5.  Translational studies on a ready-to-use intramuscular injection of penethamate for bovine mastitis.

Authors:  I G Tucker; R Jain; F Alawi; K Nanjan; O Bork
Journal:  Drug Deliv Transl Res       Date:  2018-04       Impact factor: 4.617

6.  Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain.

Authors:  Teng-Fei Li; Hui Fan; Yong-Xiang Wang
Journal:  PLoS One       Date:  2015-01-24       Impact factor: 3.240

Review 7.  From micro- to nanostructured implantable device for local anesthetic delivery.

Authors:  Laura Zorzetto; Paola Brambilla; Elena Marcello; Nora Bloise; Manuela De Gregori; Lorenzo Cobianchi; Andrea Peloso; Massimo Allegri; Livia Visai; Paola Petrini
Journal:  Int J Nanomedicine       Date:  2016-06-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.